Adjuvant Treatment of Mediastinitis with Immunoglobulins after Cardiac Surgery: The ATMI Trial

  • E. Neugebauer
  • G. Marggraf
  • R. Lefering


Immunoglobulins constitute an innovative product group with a wide spectrum of clinical use. Intravenous immunoglobulin (IVIG) solutions containing IgG in a concentration of 95% or more were introduced in the fifties primarily for the treatment of patients with humoral immunodeficiencies. In primary and secondary humoral immunodeficiencies, intravenously administered immunoglobulins replace the natural immunoglobulins and subsequently maintain the natural function of the humoral immune system. In addition, since 1981, there has been a rapid expansion of use in autoimmune diseases, in particular T-cell- and B-cell-mediated chronic neuroinflammatory diseases. The administration of high-dose IVIG is now accepted for various immune-mediated neuropathies, e.g., in the treatment of Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, and multifocal motor-neuropathy. Furthermore the National Institutes of Health (NIH) consensus conference in 1990 set up a list of indications for which there was sufficient evidence to justify IVIG application: idiopathic thrombocytopenic purpura, hypogammaglobulinemia in chronic lymphatic leukemia patients, allogenic bone-marrow transplantation, and Kawasaki syndrome. The use of IVIG in the treatment of several inflammatory disorders is a more recent trend. Potential for the clinical use of immunoglobulins has been shown for inflammatory diseases/syndromes such as rheumatoid arthritis, immunovasculitis, dermatomyositis, sepsis, and others.


Idiopathic Thrombocytopenic Purpura Discussion Forum Chronic Inflammatory Demyelinating Polyneuropathy Data Monitoring Committee Sternal Dehiscence 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hures V, Kasatchkine MD, Vassilev T, et al (1997) Pooled normal human polyspecific IgM contains neutralizing anti-idiotypes to IgG autoantibodies of autoimmune patients and protects from experimental autoimmune disease. Blood 90: 4004–4013Google Scholar
  2. 2.
    Marshall JC (1994) Infection and the host septic response contribute independently to adverse outcome in critical illness: implications for clinical trials of mediator antagonism. In: Vincent JL (ed) Yearbook of Intensive Care and Emergency Medicine. Springer, Heidelberg, pp 1–13Google Scholar
  3. 3.
    Marshall JC (1999) Organ dysfunction as an outcome measure in clinical trias. Eur J Surg Suppl 584: 62–67PubMedCrossRefGoogle Scholar
  4. 4.
    Lefering R (1999) Biostatistical outcome evaluation using TISS-28. Eur J Surg Suppl 584: 56–61PubMedCrossRefGoogle Scholar
  5. 5.
    Neugebauer E, Marggraf G, Lefering R (1999) Immunoglobulins in inflammation: Consensus-assisted protocol development and discussion forum of the ATMI trial. Eur J Surg Suppl 584Google Scholar
  6. 6.
    Kasatchkine MD, Kaveri SV (2001) Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 345: 747–755CrossRefGoogle Scholar
  7. 7.
    Loop FD, Lytle BW, Cosgrove DM, et al (1990) Sternal wound complications after isolated coronary artery bypass grafting: early and late mortality, morbidity, and cost of care. Ann Thorac Surg 49: 179–187PubMedCrossRefGoogle Scholar
  8. 8.
    Ottino G, DePaulis R, Pansini S, et al (1987) Major sternal wound infection after open-heart surgery: a multivariate analysis of risk factors in 2579 consecutive operative procedures. Ann Thorac Surg 44: 173–179PubMedCrossRefGoogle Scholar
  9. 9.
    Scarr MG, Gott VL, Townsend TR (1984) Mediastinal infection after cardiac surgery. Ann Thorac Surg 38: 415–423CrossRefGoogle Scholar
  10. 10.
    Marggraf G, Splittgerber FH, Knox M, et al (1999) Mediastinitis after cardiac surgery–epidemiology and current treatment. Eur J Surg 584: 12–16CrossRefGoogle Scholar
  11. 11.
    Solomkin JS (1999) Microbiology and antibiotic treatment: discussion forum on a study protocol on adjuvant treatment of mediastinitis with immunoglobulin (Pentaglobin®) after cardiac surgery (ATMI). Eur J Surg Suppl 584: 43–44PubMedCrossRefGoogle Scholar
  12. 12.
    Neugebauer E (1994) Multicentre trials in sepsis and septic shock–necessary prerequisites elaborated on the trial of supplement immunoglobulin treatment of Pilz et al. Theor Surg 9: 60–62Google Scholar
  13. 13.
    Opal SM (1996) Criticism of clinical trials in sepsis and organ dysfunction. In: Gullo A (ed) Sepsis and Organ Failure, Vol 4. APICE, Trieste, pp 29–41Google Scholar
  14. 14.
    Sibbald WI, Vincent IL (1995) Round table conference on clinical trials for the treatment of sepsis. Intensive Care Med 21: 184–189PubMedCrossRefGoogle Scholar
  15. 15.
    Lorenz W, Neugebauer E, Pilz G, et al (1994) Methodology of clinical trials in sepsis-introduction. Theor Surg 9: 10–11Google Scholar
  16. 16.
    Schein M, Assalia A (1994) The role of planned reoperations and laparotomy in severe intraabdominal infection: is a prospective randomized trial possible? Theor Surg 9: 38–42Google Scholar
  17. 17.
    Troidl H, McKneally MF, Mulder DS, et al (1997) Surgical Research. Basic Principles and Clinical Practice, 3rd edn. Springer, New YorkGoogle Scholar
  18. 18.
    Neugebauer E, Troidl H (1995) Consensus methods as tools to assess medical technologies. Surg Endosc 9: 481–482 (Abst)PubMedGoogle Scholar
  19. 19.
    Neugebauer E, Troidl H, Kum CK, et al (1995) The E. A. E. S. Consensus Development Conferences on laparoscopic cholecystectomy, appendectomy, and hernia repair. Consensus statements. Surg Endosc 9: 550–563PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2002

Authors and Affiliations

  • E. Neugebauer
  • G. Marggraf
  • R. Lefering

There are no affiliations available

Personalised recommendations